Design Therapeutics (DSGN) Return on Capital Employed (2021 - 2026)
Design Therapeutics recorded quarterly Return on Capital Employed of 36.1% in Q1 2026, up 6.44% quarter-over-quarter from 38.59% in Q4 2025, and down 719.0% year-over-year from 5.83% in Q1 2025.
Design Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 36.1% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 719.0% year-over-year to 36.1%; the TTM figure through Mar 2026 stood at 36.1% (down 719.0% YoY), while the FY2025 annual figure was 35.15%, down 1137.0% from the prior year.
- Return on Capital Employed came in at 36.1% for Q1 2026 at Design Therapeutics, up from 38.59% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 11.48% in Q1 2022 to a low of 38.59% in Q4 2025.
- A 5-year average of 25.98% and a median of 25.6% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 456 bps in 2024 and sank 1428 bps in 2025, its largest moves.
- Design Therapeutics' Return on Capital Employed stood at 20.05% in 2022, then tumbled by 37 bps to 27.42% in 2023, then climbed by 8 bps to 25.11% in 2024, then slumped by 54 bps to 38.59% in 2025, then grew by 6 bps to 36.1% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 36.1%, 38.59%, and 37.83% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | -36.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.10% |
| Dec 31, 2025 | -38.59% |
| Sep 30, 2025 | -37.83% |
| Jun 30, 2025 | -33.84% |
| Mar 31, 2025 | -28.92% |
| Dec 31, 2024 | -25.11% |
| Sep 30, 2024 | -23.55% |
| Jun 30, 2024 | -23.67% |
| Mar 31, 2024 | -25.60% |
| Dec 31, 2023 | -27.42% |
| Sep 30, 2023 | -28.11% |
| Jun 30, 2023 | -27.06% |
| Mar 31, 2023 | -23.43% |
| Dec 31, 2022 | -20.05% |
| Sep 30, 2022 | -16.91% |
| Jun 30, 2022 | -14.06% |
| Mar 31, 2022 | -11.48% |
| Dec 31, 2021 | -9.18% |
| Sep 30, 2021 | -7.19% |
| Jun 30, 2021 | -4.84% |
| Mar 31, 2021 | -6.07% |